Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    LCI699
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: LCI699
2 Completed A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
Condition: Hepatic Impairment
Intervention: Drug: osilodrostat
3 Active, not recruiting Safety and Efficacy of LCI699 in Cushing's Disease Patients.
Condition: Cushing's Disease
Intervention: Drug: LCI699
4 Completed A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function
Condition: Renal Impairment
Intervention: Drug: osilodrostat
5 Completed An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: Placebo;   Drug: LCI699
6 Completed Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
Condition: Primary Hyperaldosteronism
Intervention: Drug: LCI699
7 Completed A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic
Condition: Hypertension
Interventions: Drug: LCI699;   Drug: Placebo;   Drug: Eplerenone
8 Completed A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: LCI699;   Drug: Eplerenone;   Drug: Placebo
9 Recruiting Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Conditions: Cushing's Syndrome;   Ectopic Corticotropin Syndrome;   Adrenal Adenoma;   Adrenal Carcinoma;   AIMAH;   PPNAD
Intervention: Drug: Osilodrostat
10 Recruiting Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: osilodrostat;   Drug: osilodrostat Placebo

Study has passed its completion date and status has not been verified in more than two years.